compliance (1), decrease iatrogenic complications, and improve the patient's quality of life (2, 3) . Effective management of extrapyramidal side effectS depends on the ability of clinicians who prescribe neuroleptics to make accurate diagnoses.
Previous anecdotal reports have noted misdiagnosis of dystonia (4) and akathisia (5) and difficulty in distinguishing akinesia from depression (6) . There is also evidence that tardive dyskinesia is underreported by patientS (7) and that itS severity can be underesti mated by clinicians (8). Chronic parkinsonian and dyskinetic syndromes secondary to neuroleptic treat ment have been misdiagnosed in medic::a1 and neuro Ipgic clinics (9, 10) . Chronic psychiatric patientS eval uated in psychiatric clinics have been shown to have a high prevalence of mild tardive dyskinesia but only when diagnosed by expert raters (11) .
Although this anecdotal evidence suggestS major clinical problems in the accurate diagnosis of neuro leptic-induced extrapyramidal side e~ to our knowledge only one study (12) has systematically evaluated discrepancies between research and clinician diagnoses of tardive dyskinesia. The purpose of our study was to assess prospectively the level of detection of extrapyramidal syndromes achieved by the attend ing psychiatristS and psychiatric residentS routinely managing psychotic patientS in the acute inpatient psychiatric unitS of a university medical center. The results hdp to explain discrepancies in the rates of extrapyramidal side effectS between clinical and re-se~r.::h studies and have serious implications tor clini· ,ai practice and training.
We studied 58 patientS who had been consecutively admirred to the three acute inpatient units of Payne Whitnev Psvchiatric Ciinic and who met the studv criterion ot having an acute psychosis without ~ known organic mental syndrome. Within 48 hours of admission and then weekly until discharge. each pa tient was rated bv at least one researcher (P.J.W. or J.J.M.) who was blind to the clinician's diagnosis or treatment of extrapyramidal syndromes. All clinical staff were kept blind to the purpose of the study.
Ratings of E.'T:trapyramidaJ Symptoms
The presence and severity of parkinsonism, akinesia, akathisia. dvstonia. and tardive dyskinesia were deter mined bv the researchers with modifications of the Webster . Parkinson's disease scale (13) , the akinesia scale of Rifkin et al. (14) . the Van Purren akathisia scale (15) , the E:'<trapyramidal Symptom Rating Scale ( 16) , and the Abnormal Involuntary Movement Scale (AIMS) (Ii) .
The research diagnosis of tardive dyskinesia was based on an AIMS global score of 2 or higher and was confirmed by independent assessment by a second rater. For parkinsonism, akinesia. and akathisia. the ~ch diagnosis was based on a rating of 2 or higher _.111' 4-point global scale. which corresponds clinically to a range of mild (but unequivocal) to severe symp toms. Dystonia was assessed by means of the extrapy ramidal Symptom Rating Scale. which determines ei ther its presence or absence, and patient repom of a historv of dvstonia. Th~ clinicians' diagnoses of extrapyramidal side effeCts were established through chan review (by P.J.W.) after each panent's discharge. The resultS of the phYSical examination at admission, emergent phys ical findings, the patient's complaintS, nurses' observa tions, recorded quotations and handwriting samples from the patient, family commentS. and the physician's differential diagnosis of changes in the patient's behav ior consistent with neuroleptic-induced extrapyrami dal side effects were reviewed systematically. Medica tion histories (neuroleptic doses and dose changes, anticholinergic or other treatmentS, and "p.r.n." treat ments for extrapyramidal side effectS) were recorded. Clinical observations of extrapyramidal symptoms de· rived from the chan over the hospital course were contrasted with the patient's research ratings.
The followmg operational criteria for clinician nonrecognition of extrapyramidal side effects were chosen to standardize [he assessment of clinical diag stic accuracy: 1) nonrecognition by the physician or .... ~ent dyskinesia ot mild or greater severity, 2) ... e to recognize acute dystonia when its symptoms 
Characteristics of Unit Staff and Patients
The staff on each of the 24-bed units included two full-time supervising attending psychiatrists, four psy chiatry residentS in postgraduate year 2, and one inpatient chief resident in postgraduate year 4. The data were colleCted between August and October, the second through founh months of the residents' sec ond-year inpatient experience. The residentS had also completed 5 months of psychiatric training during their internships and a course on the inpatient treat ment of acute psychosis. All trainees had at least twO attending supervisors who periodicaily examined all of their patientS.
Of the 58 patientS examined, 48 received at least 1 week of continuous neuroleptic treatment and com pleted at least two research ratings of extrapyramidal side effeCts. These 48 patientS were relatively young (mean:!:5D age=27.4:!:16.9 years) and consisted of 29 females and 19 males. Their DSM-IIl diagnoses at discharge included schizophrenia (N -= 19), schizoaffec tive disorder (N= 12). schizophreniform disorder (N=3), bipolar disorder, manic or mixed (N=9), and major depression with psychotic features (N = 5). Their mean:!:5D length of stay was 28.0: 14.6 days, and they received 3.6: l.i research ratings. The average dose of neuroleptics during acute treatment was 1401: 1064 mglday of chlorpromazine equivalentS, and the range was 200-5000 mglday. Initial anticho linergic prophylaxis was begun for 29 patients (60%), and eventually 44 patients (92%) received adiuvant anticholinergic therapy, Of note in the clinical man agement of this group are the relatively high neurolep tic doses used and the high frequency of administration of anticholinergic agents.
The number of patientS in whom extrapyramidal side effects w"ere identified bv means of the standard research assessments was high. Of the 48 patientS, 29 developed parkinsonian signs, 23 had akinesia (all of these patients had coexisting parkinsonian signs), 2i had akathisia. three had dystonic reactions during research examinations, and 11 had dvstonias accord ing to the combination of clinical diagnosis and re search dystonia history. Ten patients (out of the orig inal 58) had tardive dyskinesia.
RESULTS
Each patient who had extrapyramidal side effectS according to the researcher's diagnOSis was categorized in terms of presence or absence of an accurate clinical diagnosis. bS um ot the AIMS extremity movement Items divided by the sum of the AIMS facial and oral movement irems.
cant rates of disagreement betWeen the research and clinical diagnoses across all types of extrapyramidal , side effects. Except for three cases of dystonia. all the cases of extrapyramidal side effects documented by the clinical method. were picked up by the research method, but many cases were missed by the clinicians but detected bv the research assessment. There was no significant difference betWeen the patientS whose extrapyramidal side effects were and were not recog nized clinically in terms of demographic charaCteris tics. discharge diagnoses. rates of anticholinergic pro phylaxis. or (except for akathisia) neuroleptic doses. Only one of the 10 patients with tardive dyskinesia was accurately diagnosed by the clinicians. Among the nine patients with undiagnosed cases, three had nurse or physician notes that mentioned abnormal dyskinetic movements but no follow-up diagnosis of tardive dyskinesia. Considering these three cases as recognized cases of tardive dyskinesia allows a comparison of four "recognized" and six unrecognized cases. Overall se· veriey on the global AlMS did not differentiate the patients with recognized and unrecognized cases (see table 2 ). However, oral movementS were significantly more severe in the patients with recognized tardive dyskinesia. whereas the patients with unrecognized cases had a predominance of extremity movements.
Mild parkinsonism (tremor, rigidity, micrographia, or decreased fine motor coordinanon) was found bv the researchers in 29 patients. Rigidity was the most severe clinical sign in 26 of them. In 17 cases the parkinsonism was accurately diagnosed by the clini cian. Of the 12 cases that were inaccurately diagnosed. eight were missed completely, two were identified with a delav of more than 1 week, and two were underrated in global severity. The mean researcher ratings of global severity for the unrecognized and recognized cases of parkinsonism did not significantly differ (table 2) , suggesting that overall clinical severity did nOt determine nonrecognition.
Of the 23 researcher-diagnosed cases of akinesia, 14
were accurately identified by clinicians. Among the nine missed cases, five had no diagnosis or no mention of the differential diagnosis of akinesia, three received the~ikely misdiagnosis of "depression" (without con sideration of the possibility of akinesia despite the temporal correlation of akinesia with neuroleptic ad ministration), and one was severe but was rated by clinical staff as "mild" and received no treatment.
Severity of symptoms prediaed clinical diagnostic accuracy but in an unexpected direction. The cases missed by the clinicians had significantly more severe symptoms thaI) the recognized cases (table 2) . Patients with misdiagnosed akinesia were also significantly more likely to suffer from coexisting akathisia (t=3.8, df=21, p<.OOl).
The clinical staff inaccurately diagnosed 20 of the 27 researcher·diagnosed cases of akathisia. The clinical errors consisted of nine cases in which the akathisia went unnoticed, seven cases of errors in the differential diagnosis of agitationlresricssnessluac:ring out" after recent increases in neuroleptic dose. and four cases of delay in diagnosis of more than 1 week. Underrecogni tion of akathisia was significantly associated with lower severity research ratings. suggesting that milder (or less reliably ratable) forms of akathisia are missed in clinicians' assessments. In addition, the patients with unrecognized akathisia received higher neurolep' tic doses than the patients with diagnosed akathisia (mean=5D= 1700::955 versus 1007::406 mgtday of chlorpromazine equivalents; t=2.6. df=25, p<.01). The patients with undiagnosed akathisia also suffered from more severe coexisting akinesia than those with accurate akathisia diagnoses (t=2.8, df=25, 1'<.05).
Acute dystonic reactions were difficult to assess accurately on the basis of patient reports because of the patients' poor recall and unreliable descriptions of dysronias. Chart review revealed three cases of dystonias missed by systematic research assessment with the Extrapyramidal Symptom Rating Scale. !n contrast, however, three patients had acute dystonias during research examinations (two had oculogyric crises and one had neck torricollis); all occurred early in the course of neuroleptic treatment. In all three cases, the patients complained of their symptoms to the nursing staff. Two were misdiagnosed: one was descnbed as "psychotic behavior" by the physician on call, and the other was considered "hysteric" by the nursing staff and received no physician evaluation. No treatment was given to either patient.
Each patient (N=16) who gave a preadmission history of disuessing acute extrapyramidal side effects during previous neuroleptic exposure received anticho linergic prophylaxis. However, presence or absence of anticholinergic prophylaxis was not a predictor of subsequent physician nonrecognition of extrapyrami dal syndromes. Every case of acute extrapyramidal side effeCts that was dinically diagnosed was initially treated with adjuvant medication. never with a reduc tion of neuroleptic dose.
DISCUSSION
The maior finding of this study was a high rate of dinician nonrecognition of extrapyramidal side effects. This finding suggests that wide differences in the frequency of extrapyramidal side effects across studies may be partly due to variations in the experrise and sensitivity of the examiners. These results definitely point to severe limitations in using chart review alone in quality assurance studies to determine the nature and extent of extrapyramidal side effects. Most impor tant dinically, however, are the serious yet correctable blind spotS in the clinical diagnosis of extrapyramidal side effeCts. We wish to emphasize that there was nothing difficult about the research evaluation of extrapyramidal symptoms and that dinical nonrecog nition of extrapyramidal side effeers can be reduced with better training and systematic attention to this problem.
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Tardive dyskinesia, despite its persistent nature. is often missed. especially when its symptoms involve the extremities rather than the "classic" orobuccal areas. This selective nonrecognition of extremity dyskinesias may arise for several reasons: this form of tardive dyskinesia is less well known to clinicians, patients may disguise their hand dyskinesias better than oral ones. hand dyskinesias often occur only when the patient is walking, shoes usually are not removed during examinations, and hand choreas may be mis taken for tremors. Physicians should inspect the ex tremities for choreiform movements and generally have a high index of suspicion for any form of tardive dyskinesia in any patient receiving antipsychotic med ications.
Severe forms of akinesia tend to be more frequently underrecognized than milder cases. This may be be cause severely akinetic patients complain less about their symptoms than patients with milder cases or because severe akinesia is more likely to be misdiag nosed as depression. Akinesia should be considered in the differential diagnosis of any patient taking neuro leptics who becomes amotivational, depressed. lethar gic, or slowed down. Staff cannot expect the patient to report these changes spontaneously. .. The higher neuroleptic doses found in the patients with unrecognized akathisia than in those with recog nized akathisia may reflect the eventual appropriate lowering of neuroleptic dose when the akathisia was diagnosed. For those patients whose akathisia is mis diagnosed as agitation or psychosis, the neuroleptic dose will instead be increased. Akathisia also seemed to be missed when it presented behaviorally (i.e., .IS an elopement or incident requiring seclusion) or when!::e patient was tOO psychotic, disorganized, or akinetic .:, complain of akathisia. In the very psychotic patient, the subjective experience of akathisia can only be assessed (if at all) by a direct. focused patient inter view. In fact, akathisia should be considered for anv restlessness, agitation, or acting-out behavior of recent onset that temporally coincides with escalating neuro leptic dose. even if the patient does not voluntarily mentjion severe inner restlessness. The clinician should not rule OUt akathisia until completing such a focused, active inquiry for subjective restlessness andlor behav ioral agitation. Dystonia was the only extrapyramidal side effect missed by research rating but not clinical diagnosis. suggesting that dystonias cannot be accurately ascer tained by interview alone. The intermittent nature of dystonias usually requires that an assessment be made by means of patient history rather than physical exam ination. Unfortunately, the historical method for diag nosing dystonias proved to be unreliable. Even more discouraging was what happened with the acute dystonias actually observed by both researchers and staff. Despite the small number of such cases, an unequivocal rate of 67% for the misdiagnosis of rypical and classic dystonias is noteworthy, and it seems that textbook cases of acute dystonia are still '.I::.LRIJLl:.I'TK.. ,:'.Ul.Ll::.D \,iV\ 1::.;"11::.;>'1 iJl:)lJI: WtK;) frequently attributed to psvchopathology. The Jyston-' ias in our study seemed to be m1ssed bec.:l.use they occurred shortly after admission. when the staff did not know the' patients. some ot whom were very psychotic. Other immediate management issues seemed to preempt the careful observation necessary to make a diagnosis of dystonia. We therefore recom mend that aU inpatient staff automatically consider any new muscle spasm or posturing arising e:lrly in ne~roleptic treatment to be a dystonic reactio~.
Other useful diagnostic techniques include a tocused clinical interview with repeated attempts to elicit com plaints of aU subtypes of extrapyramidal side effectS. interviewing family members about the patient's cur rent behavior and whether it coincides with extrapy ramidal side effects in the past. and being cautious about any report or past history of "hysterical" or "psychotic" abnormal movements. Another helpful technique is a review of the timing and doses of all medications administered to find pharmacologic cor relates with the undiagnosed behavior. Graphing the medication record alongside recorded observations of the patient's symptoms can highlight medication-in duced toxicity patterns.
The clinicians in this studv consistently provided anticholinergic prophylaxis for patients who gave prior histories of extrapyramidal side effects. They also promptly treated diagnosed extrapyramidal symptoms with adjuvant medication. However. it is striking that neuroleptic dose reduction was never the initial treat ment when such a symptom was recognized. It seems that lowering the neuroleptic dose should have been , used more often. In addition. using prophylactic anti cholinergic agents did not improve the recognition rate. Therefore. clinicians should not be lulled into a false sense of security by the belief that anticholinergic prophylaxis solves the problems of accurately assess ing extrapyramidal side effects. This study of clinician versus research diagnosis of extrapyramidal symptoms has several limitations. The clinician diagnoses were determined by means of rer rospective chart review. which depends on accurate chart documentation and may have underestimated the rates of actual clinician diagnoses of extrapyrami dal side effects. This retrospective method was chosen to avoid alerting the clinicians to the nature of the study. However. since the necessity for documenting extrapyramidal side effects is carefully emphasized at our institution and the cham are well documented in other ways. it seems unlikely that a diagnosis of an extrapyramidal syndrome would not have become part ot the treatment record.
Another potential methodologic problem of this studv is the lack of research rater blindness to the purPose of the study. This may have inflated the number of research diagnoses of extrapyramidal side effects. resulting in an artificially high rate of clinical nonrecognition. However. the rates of clinical nonrecognition across all subtypes of extrapyramidal symptoms (except akathisial did not proportionately 1152 decrease as the researcher-rated severity increased: It was not lust subtle extrapyramidal effeas that were not recognized. but unequivocal ones as well. Weekly movement disorder resea.rch rounds served as reliabil ity checks of the primary rilters (P.J.W. and J.J.M.). Therefore. we feel researcher bias does not explain these results.
Another concern is that there is a high degree of intrinsic overlap in the presentations of certain extra pyramidal side effects and primary psychiatric diag noses and that the research rater mav have mistaken primary psychopathology for extrapyramidal side ef fects. This is most possible for the research-diagnosed akinesia and akathisia. Although we cannot rule out the possibility that symptom overlap increased the researcher diagnoses of extrapyramidal side effectS. the same difficulties face the treating clinical teams, who need to routinelv consider akathisia and akinesia in the differential dia~oses of sudden. unexplained behav ioral changes (4) (5) (6) . Indeed. the researchers perform ing the chart reviews accepted as an accurate clinical diagnosis any documentation that included extrapy ramidal side effectS as part of the differential diagnosis regardless of the final conclusion. Moreover. seemingly "hard" and unequivocal neurologic findings such as dystonia and dyskinesia were missed at even higher rates than akinesia and akathisia! Other methodologic questions relate to the rele vance and generalizability of these findings to nation wide patterns in the diagnosis of extrapyramidal side effectS. It is possible that these results reflect a partic ular blind spOt of the institution where the study was performed. A related issue is the riming of the study, which occurred early in the 12-month training cycle; the results may differ with more experienced residents. We think that this is an inadequate explanation of our findings given that the residents were well qualified and were supervised by full-time attending physicians. Furthermore. a similar chart review conducted at a Veterans Administration teaching hospital (12) also demonstrated a is% rate of nonrecognition of tardive dyskinesia by clinical staff. strongly suggesting the possibility of a nationwide pattern of nonrecognition of e«trapyramidal side effects. We suspect that the underdiagnosis of extrapyramidal side effects reflects the clinical limitations of attending and resident psy chiatrists who are not specifically and extensively trained in the evaluation of extrapyramidal symptoms and who do not systematically rate them at regular intervals.
The ability to perform a sophisticated assessment of extrapyramidal side effects is not easily learned and requires specific training. This study underscores the need for careful supervision. training. and attention to the accurate diagnosis of extrapyramidal side effects. It also seems clear that repeated and systematic evalua tion of extrapyramidal symptoms with standardized measures (at least every 2 weeks and at admission and discharge) should be made routine on every acute inpatient unit. General psychiatric interviewing meth- 
